Summary by Futu AI
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.